Literature DB >> 12584563

Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.

Gaëlle Bougeard1, Laurence Brugières, Agnès Chompret, Paul Gesta, Françoise Charbonnier, Alexander Valent, Cosette Martin, Grégory Raux, Jean Feunteun, Brigitte Bressac-de Paillerets, Thierry Frébourg.   

Abstract

The absence of detectable germline TP53 mutations in a fraction of families with Li-Fraumeni syndrome (LFS) has suggested the involvement of other genes, but this hypothesis remains controversial. The density of Alu repeats within the TP53 gene led us to search genomic rearrangements of TP53 in families without detectable TP53 mutation. To this aim, we adapted the quantitative multiplex PCR of short fluorescent fragments (QMPSF) method to the analysis of the 11 exons of TP53. We analysed 98 families, either fulfilling (six families) or partially meeting (92 families) the criteria for LFS, and in which classical methods had failed to reveal TP53 alterations. We identified, in a large family fulfilling the criteria for LFS, a complete heterozygous deletion of TP53. Additional QMPSF analyses indicated that this deletion, which partially removed the centromeric FLJ10385 locus, covered approximately 45 kb. This deletion was shown to result from a complex rearrangement involving two distinct Alu-mediated recombinations. We conclude that TP53 germline rearrangements occur as rare events, but must be considered in LFS families without detectable point TP53 mutation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584563     DOI: 10.1038/sj.onc.1206155

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes.

Authors:  Adam Shlien; Berivan Baskin; Maria Isabel W Achatz; Dimitrios J Stavropoulos; Kim E Nichols; Louanne Hudgins; Chantal F Morel; Margaret P Adam; Nataliya Zhukova; Lianne Rotin; Ana Novokmet; Harriet Druker; Mary Shago; Peter N Ray; Pierre Hainaut; David Malkin
Journal:  Am J Hum Genet       Date:  2010-11-12       Impact factor: 11.025

2.  Molecular evaluation of foetuses with holoprosencephaly shows high incidence of microdeletions in the HPE genes.

Authors:  Claude Bendavid; Christèle Dubourg; Isabelle Gicquel; Laurent Pasquier; Pascale Saugier-Veber; Marie-Renée Durou; Sylvie Jaillard; Thierry Frébourg; Bassem R Haddad; Catherine Henry; Sylvie Odent; Véronique David
Journal:  Hum Genet       Date:  2005-12-02       Impact factor: 4.132

3.  Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.

Authors:  Mariëlle W G Ruijs; Senno Verhoef; Gea Wigbout; Roelof Pruntel; Arno N Floore; Daphne de Jong; Laura J van T Veer; Fred H Menko
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 4.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

Review 5.  Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention.

Authors:  María Sereno; Cristina Aguayo; Carmen Guillén Ponce; César Gómez-Raposo; Francisco Zambrana; Miriam Gómez-López; Enrique Casado
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

Review 6.  Clinical management of hereditary breast cancer syndromes.

Authors:  Amy S Clark; Susan M Domchek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-01       Impact factor: 2.673

Review 7.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

8.  Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours.

Authors:  Juliette Aury-Landas; Gaëlle Bougeard; Hélène Castel; Hector Hernandez-Vargas; Aurélie Drouet; Jean-Baptiste Latouche; Marie-Thérèse Schouft; Claude Férec; Dominique Leroux; Christine Lasset; Isabelle Coupier; Olivier Caron; Zdenko Herceg; Thierry Frebourg; Jean-Michel Flaman
Journal:  Eur J Hum Genet       Date:  2013-04-24       Impact factor: 4.246

9.  Clinical utility of array comparative genomic hybridization: uncovering tumor susceptibility in individuals with developmental delay.

Authors:  Margaret P Adam; April N Justice; Susan Schelley; Andrea Kwan; Louanne Hudgins; Christa L Martin
Journal:  J Pediatr       Date:  2009-01       Impact factor: 4.406

10.  Copy number variations and cancer.

Authors:  Adam Shlien; David Malkin
Journal:  Genome Med       Date:  2009-06-16       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.